Loading clinical trials...

Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma

NCT00190424•Assistance Publique - Hôpitaux de Paris

Summary

The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Glioblastoma
•Karnofsky Performance Status ≥ 60%

Exclusion Criteria

•Severe or uncontrolled systemic disease
•Active auto-immune disease
•Uncontrolled epilepsia
•Platelets \< 100 000/mm3 ; or Neutrophils \<500 /mm3 ; or lymphocytes \<300/ mm3

Locations (2)

Hopital Salpetriere

Paris, Paris, France

Hopital Lariboisiere

Paris, Paris, France

Key Dates

Start Date

September 1, 2005

Primary Completion Date

October 1, 2008

Completion Date

October 1, 2010

Last Updated

December 13, 2012

Enrollment

ACTUAL participants

Conditions

Glioblastoma

Interventions

CpG-ODN

DRUG

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 13, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

Inclusion Criteria

Exclusion Criteria

Targeted Pediatric High-Grade Glioma Therapy

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma